1. Point: should triple inhaled therapy be considered in all patients with group E COPD? Yes;Adrish;Chest,2024
2. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary;Agustí;Eur Respir J,2023
3. Triple therapy for all patients with severe, symptomatic COPD at risk of exacerbations;Papi;Eur Respir J,2019
4. Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study
5. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial;Han;Am J Respir Crit Care Med,2020